| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.27 | 5e-07 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.29 | 3e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.27 | 9e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-05 |